nodes	percent_of_prediction	percent_of_DWPC	metapath
Cysteamine—MPO—Carboplatin—bone cancer	0.425	0.539	CbGbCtD
Cysteamine—MPO—Cisplatin—bone cancer	0.363	0.461	CbGbCtD
Cysteamine—SST—cranial nerve—bone cancer	0.0228	0.397	CbGeAlD
Cysteamine—SST—vertebral column—bone cancer	0.0224	0.39	CbGeAlD
Cysteamine—SST—SIDS Susceptibility Pathways—FEV—bone cancer	0.0103	0.125	CbGpPWpGaD
Cysteamine—MPO—Folate Metabolism—FOLR1—bone cancer	0.00693	0.0843	CbGpPWpGaD
Cysteamine—SST—Mecp2 and Associated Rett Syndrome—EZH2—bone cancer	0.00574	0.0698	CbGpPWpGaD
Cysteamine—Gastrointestinal ulcer haemorrhage—Cisplatin—bone cancer	0.00543	0.0759	CcSEcCtD
Cysteamine—NPY2R—Circadian rythm related genes—TNFRSF11A—bone cancer	0.00519	0.0631	CbGpPWpGaD
Cysteamine—SST—connective tissue—bone cancer	0.00471	0.082	CbGeAlD
Cysteamine—Gastrointestinal ulcer—Methotrexate—bone cancer	0.00369	0.0516	CcSEcCtD
Cysteamine—Papilloedema—Cisplatin—bone cancer	0.00327	0.0458	CcSEcCtD
Cysteamine—SST—spinal cord—bone cancer	0.00313	0.0543	CbGeAlD
Cysteamine—Gastrointestinal ulcer haemorrhage—Methotrexate—bone cancer	0.00298	0.0417	CcSEcCtD
Cysteamine—SST—G alpha (i) signalling events—GRM4—bone cancer	0.0029	0.0352	CbGpPWpGaD
Cysteamine—SST—G alpha (i) signalling events—RGS1—bone cancer	0.0029	0.0352	CbGpPWpGaD
Cysteamine—NPY2R—G alpha (i) signalling events—GRM4—bone cancer	0.00278	0.0337	CbGpPWpGaD
Cysteamine—NPY2R—G alpha (i) signalling events—RGS1—bone cancer	0.00278	0.0337	CbGpPWpGaD
Cysteamine—MPO—Folate Metabolism—DHFR—bone cancer	0.0019	0.0231	CbGpPWpGaD
Cysteamine—MPO—connective tissue—bone cancer	0.0019	0.033	CbGeAlD
Cysteamine—NPY2R—Circadian rythm related genes—GNA11—bone cancer	0.00176	0.0214	CbGpPWpGaD
Cysteamine—SST—GPCR ligand binding—GRM4—bone cancer	0.00175	0.0213	CbGpPWpGaD
Cysteamine—NPY2R—Circadian rythm related genes—EZH2—bone cancer	0.00175	0.0213	CbGpPWpGaD
Cysteamine—Optic neuritis—Cisplatin—bone cancer	0.00169	0.0237	CcSEcCtD
Cysteamine—NPY2R—GPCR ligand binding—GRM4—bone cancer	0.00168	0.0204	CbGpPWpGaD
Cysteamine—SST—GPCR ligand binding—GRM1—bone cancer	0.00152	0.0185	CbGpPWpGaD
Cysteamine—NPY2R—GPCR ligand binding—GRM1—bone cancer	0.00146	0.0177	CbGpPWpGaD
Cysteamine—MPO—bone marrow—bone cancer	0.00126	0.022	CbGeAlD
Cysteamine—MPO—spinal cord—bone cancer	0.00126	0.0219	CbGeAlD
Cysteamine—Appetite absent—Methotrexate—bone cancer	0.00115	0.0161	CcSEcCtD
Cysteamine—SST—GPCR ligand binding—SMO—bone cancer	0.00107	0.013	CbGpPWpGaD
Cysteamine—NPY2R—GPCR ligand binding—SMO—bone cancer	0.00103	0.0125	CbGpPWpGaD
Cysteamine—Body temperature increased—Carboplatin—bone cancer	0.001	0.014	CcSEcCtD
Cysteamine—SST—GPCR downstream signaling—RGS1—bone cancer	0.000991	0.012	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—GRM4—bone cancer	0.000991	0.012	CbGpPWpGaD
Cysteamine—NPY2R—Circadian rythm related genes—CDK4—bone cancer	0.000988	0.012	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—RGS1—bone cancer	0.00095	0.0115	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—GRM4—bone cancer	0.00095	0.0115	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—RGS1—bone cancer	0.0009	0.0109	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—GRM4—bone cancer	0.0009	0.0109	CbGpPWpGaD
Cysteamine—Encephalopathy—Methotrexate—bone cancer	0.00089	0.0124	CcSEcCtD
Cysteamine—Optic neuritis—Epirubicin—bone cancer	0.000869	0.0122	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—GRM4—bone cancer	0.000862	0.0105	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—RGS1—bone cancer	0.000862	0.0105	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—GRM1—bone cancer	0.000859	0.0104	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—GRM1—bone cancer	0.000823	0.01	CbGpPWpGaD
Cysteamine—SST—SIDS Susceptibility Pathways—JUN—bone cancer	0.000813	0.00989	CbGpPWpGaD
Cysteamine—Optic neuritis—Doxorubicin—bone cancer	0.000804	0.0112	CcSEcCtD
Cysteamine—Redness—Epirubicin—bone cancer	0.000792	0.0111	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—GRM1—bone cancer	0.00078	0.00948	CbGpPWpGaD
Cysteamine—MPO—C-MYB transcription factor network—KIT—bone cancer	0.000776	0.00943	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—GRM1—bone cancer	0.000748	0.00909	CbGpPWpGaD
Cysteamine—Redness—Doxorubicin—bone cancer	0.000733	0.0102	CcSEcCtD
Cysteamine—Scotoma—Epirubicin—bone cancer	0.000704	0.00984	CcSEcCtD
Cysteamine—Dehydration—Cisplatin—bone cancer	0.000703	0.00983	CcSEcCtD
Cysteamine—Scotoma—Doxorubicin—bone cancer	0.000651	0.00911	CcSEcCtD
Cysteamine—NPY2R—Circadian rythm related genes—JUN—bone cancer	0.000637	0.00774	CbGpPWpGaD
Cysteamine—Bone disorder—Methotrexate—bone cancer	0.000633	0.00884	CcSEcCtD
Cysteamine—Bone disorder—Epirubicin—bone cancer	0.000592	0.00828	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—PTGS2—bone cancer	0.000589	0.00716	CbGpPWpGaD
Cysteamine—Thinking abnormal—Epirubicin—bone cancer	0.000584	0.00817	CcSEcCtD
Cysteamine—Renal failure—Cisplatin—bone cancer	0.000572	0.00801	CcSEcCtD
Cysteamine—MPO—Selenium Micronutrient Network—PTGS2—bone cancer	0.000568	0.0069	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—GNA11—bone cancer	0.000553	0.00673	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—SMO—bone cancer	0.00055	0.00668	CbGpPWpGaD
Cysteamine—Bone disorder—Doxorubicin—bone cancer	0.000548	0.00766	CcSEcCtD
Cysteamine—Thinking abnormal—Doxorubicin—bone cancer	0.00054	0.00756	CcSEcCtD
Cysteamine—Phosphatase alkaline increased—Epirubicin—bone cancer	0.000535	0.00748	CcSEcCtD
Cysteamine—SST—Signaling Pathways—RGS1—bone cancer	0.000531	0.00646	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—GRM4—bone cancer	0.000531	0.00646	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—GNA11—bone cancer	0.000531	0.00645	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—SMO—bone cancer	0.000527	0.00641	CbGpPWpGaD
Cysteamine—Urinary tract disorder—Cisplatin—bone cancer	0.000516	0.00722	CcSEcCtD
Cysteamine—Connective tissue disorder—Cisplatin—bone cancer	0.000514	0.00718	CcSEcCtD
Cysteamine—Urethral disorder—Cisplatin—bone cancer	0.000512	0.00717	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—RGS1—bone cancer	0.00051	0.00619	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—GRM4—bone cancer	0.00051	0.00619	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—GNA11—bone cancer	0.000503	0.00611	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—IL3—bone cancer	0.000502	0.0061	CbGpPWpGaD
Cysteamine—Phosphatase alkaline increased—Doxorubicin—bone cancer	0.000495	0.00692	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—GNA11—bone cancer	0.000482	0.00586	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—IL3—bone cancer	0.000481	0.00585	CbGpPWpGaD
Cysteamine—Immune system disorder—Cisplatin—bone cancer	0.000472	0.0066	CcSEcCtD
Cysteamine—Mental disability—Epirubicin—bone cancer	0.000464	0.00649	CcSEcCtD
Cysteamine—SST—Signaling Pathways—GRM1—bone cancer	0.000461	0.0056	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—IL3—bone cancer	0.000456	0.00554	CbGpPWpGaD
Cysteamine—Malnutrition—Cisplatin—bone cancer	0.000455	0.00636	CcSEcCtD
Cysteamine—Erythema—Cisplatin—bone cancer	0.000455	0.00636	CcSEcCtD
Cysteamine—Blood alkaline phosphatase increased—Epirubicin—bone cancer	0.000446	0.00624	CcSEcCtD
Cysteamine—Hepatic function abnormal—Epirubicin—bone cancer	0.000444	0.00621	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—GRM1—bone cancer	0.000442	0.00537	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—IL3—bone cancer	0.000437	0.00531	CbGpPWpGaD
Cysteamine—Eye pain—Epirubicin—bone cancer	0.00043	0.00601	CcSEcCtD
Cysteamine—Mental disability—Doxorubicin—bone cancer	0.000429	0.006	CcSEcCtD
Cysteamine—Tremor—Cisplatin—bone cancer	0.000426	0.00596	CcSEcCtD
Cysteamine—MPO—Folate Metabolism—TP53—bone cancer	0.000425	0.00517	CbGpPWpGaD
Cysteamine—Lethargy—Methotrexate—bone cancer	0.000423	0.00592	CcSEcCtD
Cysteamine—Anaemia—Cisplatin—bone cancer	0.000421	0.00588	CcSEcCtD
Cysteamine—NPY2R—Circadian rythm related genes—TP53—bone cancer	0.00042	0.00511	CbGpPWpGaD
Cysteamine—Blood alkaline phosphatase increased—Doxorubicin—bone cancer	0.000413	0.00577	CcSEcCtD
Cysteamine—Hepatic function abnormal—Doxorubicin—bone cancer	0.000411	0.00575	CcSEcCtD
Cysteamine—Leukopenia—Cisplatin—bone cancer	0.000407	0.0057	CcSEcCtD
Cysteamine—Eye pain—Doxorubicin—bone cancer	0.000398	0.00556	CcSEcCtD
Cysteamine—Lethargy—Epirubicin—bone cancer	0.000396	0.00554	CcSEcCtD
Cysteamine—Convulsion—Cisplatin—bone cancer	0.000394	0.00551	CcSEcCtD
Cysteamine—Mood swings—Methotrexate—bone cancer	0.000393	0.00549	CcSEcCtD
Cysteamine—Ataxia—Methotrexate—bone cancer	0.00039	0.00545	CcSEcCtD
Cysteamine—Pain in extremity—Epirubicin—bone cancer	0.000388	0.00543	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000385	0.00538	CcSEcCtD
Cysteamine—Liver function test abnormal—Methotrexate—bone cancer	0.000383	0.00535	CcSEcCtD
Cysteamine—Discomfort—Cisplatin—bone cancer	0.000383	0.00535	CcSEcCtD
Cysteamine—Affect lability—Epirubicin—bone cancer	0.000382	0.00534	CcSEcCtD
Cysteamine—Anaphylactic shock—Cisplatin—bone cancer	0.000371	0.00519	CcSEcCtD
Cysteamine—Mood swings—Epirubicin—bone cancer	0.000368	0.00514	CcSEcCtD
Cysteamine—Lethargy—Doxorubicin—bone cancer	0.000366	0.00512	CcSEcCtD
Cysteamine—Ataxia—Epirubicin—bone cancer	0.000365	0.0051	CcSEcCtD
Cysteamine—Nervous system disorder—Cisplatin—bone cancer	0.000364	0.00509	CcSEcCtD
Cysteamine—Dehydration—Epirubicin—bone cancer	0.000361	0.00505	CcSEcCtD
Cysteamine—Skin disorder—Cisplatin—bone cancer	0.000361	0.00505	CcSEcCtD
Cysteamine—Pain in extremity—Doxorubicin—bone cancer	0.000359	0.00502	CcSEcCtD
Cysteamine—Liver function test abnormal—Epirubicin—bone cancer	0.000358	0.00501	CcSEcCtD
Cysteamine—Anorexia—Cisplatin—bone cancer	0.000354	0.00495	CcSEcCtD
Cysteamine—Affect lability—Doxorubicin—bone cancer	0.000353	0.00494	CcSEcCtD
Cysteamine—Mood swings—Doxorubicin—bone cancer	0.00034	0.00476	CcSEcCtD
Cysteamine—Ataxia—Doxorubicin—bone cancer	0.000338	0.00472	CcSEcCtD
Cysteamine—Dehydration—Doxorubicin—bone cancer	0.000334	0.00467	CcSEcCtD
Cysteamine—Liver function test abnormal—Doxorubicin—bone cancer	0.000332	0.00464	CcSEcCtD
Cysteamine—SST—Signaling Pathways—SMO—bone cancer	0.000325	0.00395	CbGpPWpGaD
Cysteamine—Decreased appetite—Cisplatin—bone cancer	0.000323	0.00452	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Cisplatin—bone cancer	0.000321	0.00448	CcSEcCtD
Cysteamine—Renal failure—Methotrexate—bone cancer	0.000314	0.00439	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—SMO—bone cancer	0.000311	0.00378	CbGpPWpGaD
Cysteamine—Feeling abnormal—Cisplatin—bone cancer	0.000306	0.00428	CcSEcCtD
Cysteamine—SST—Signaling Pathways—GNA11—bone cancer	0.000297	0.00361	CbGpPWpGaD
Cysteamine—Renal failure—Epirubicin—bone cancer	0.000294	0.00411	CcSEcCtD
Cysteamine—Body temperature increased—Cisplatin—bone cancer	0.000294	0.00411	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—GNA11—bone cancer	0.000285	0.00346	CbGpPWpGaD
Cysteamine—Urinary tract disorder—Methotrexate—bone cancer	0.000283	0.00396	CcSEcCtD
Cysteamine—Urethral disorder—Methotrexate—bone cancer	0.000281	0.00393	CcSEcCtD
Cysteamine—SST—Signaling Pathways—ATF1—bone cancer	0.000276	0.00336	CbGpPWpGaD
Cysteamine—Hypersensitivity—Cisplatin—bone cancer	0.000274	0.00383	CcSEcCtD
Cysteamine—Renal failure—Doxorubicin—bone cancer	0.000272	0.0038	CcSEcCtD
Cysteamine—SST—Signaling Pathways—IL3—bone cancer	0.000269	0.00327	CbGpPWpGaD
Cysteamine—Asthenia—Cisplatin—bone cancer	0.000266	0.00373	CcSEcCtD
Cysteamine—Urinary tract disorder—Epirubicin—bone cancer	0.000265	0.00371	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—ATF1—bone cancer	0.000265	0.00322	CbGpPWpGaD
Cysteamine—Connective tissue disorder—Epirubicin—bone cancer	0.000264	0.00369	CcSEcCtD
Cysteamine—Urethral disorder—Epirubicin—bone cancer	0.000263	0.00368	CcSEcCtD
Cysteamine—Immune system disorder—Methotrexate—bone cancer	0.000259	0.00362	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—IL3—bone cancer	0.000258	0.00314	CbGpPWpGaD
Cysteamine—Diarrhoea—Cisplatin—bone cancer	0.000254	0.00355	CcSEcCtD
Cysteamine—Mental disorder—Methotrexate—bone cancer	0.000251	0.00351	CcSEcCtD
Cysteamine—Erythema—Methotrexate—bone cancer	0.00025	0.00349	CcSEcCtD
Cysteamine—Malnutrition—Methotrexate—bone cancer	0.00025	0.00349	CcSEcCtD
Cysteamine—Urinary tract disorder—Doxorubicin—bone cancer	0.000245	0.00343	CcSEcCtD
Cysteamine—Connective tissue disorder—Doxorubicin—bone cancer	0.000244	0.00341	CcSEcCtD
Cysteamine—Urethral disorder—Doxorubicin—bone cancer	0.000244	0.00341	CcSEcCtD
Cysteamine—Immune system disorder—Epirubicin—bone cancer	0.000243	0.00339	CcSEcCtD
Cysteamine—Vomiting—Cisplatin—bone cancer	0.000236	0.0033	CcSEcCtD
Cysteamine—Mental disorder—Epirubicin—bone cancer	0.000235	0.00329	CcSEcCtD
Cysteamine—Rash—Cisplatin—bone cancer	0.000234	0.00327	CcSEcCtD
Cysteamine—Dermatitis—Cisplatin—bone cancer	0.000234	0.00327	CcSEcCtD
Cysteamine—Malnutrition—Epirubicin—bone cancer	0.000234	0.00327	CcSEcCtD
Cysteamine—Erythema—Epirubicin—bone cancer	0.000234	0.00327	CcSEcCtD
Cysteamine—Anaemia—Methotrexate—bone cancer	0.000231	0.00323	CcSEcCtD
Cysteamine—SST—Signaling Pathways—TGFBR2—bone cancer	0.00023	0.0028	CbGpPWpGaD
Cysteamine—Tension—Epirubicin—bone cancer	0.000229	0.00321	CcSEcCtD
Cysteamine—Nervousness—Epirubicin—bone cancer	0.000227	0.00317	CcSEcCtD
Cysteamine—Immune system disorder—Doxorubicin—bone cancer	0.000224	0.00314	CcSEcCtD
Cysteamine—Leukopenia—Methotrexate—bone cancer	0.000224	0.00313	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—TGFBR2—bone cancer	0.000221	0.00268	CbGpPWpGaD
Cysteamine—Nausea—Cisplatin—bone cancer	0.000221	0.00309	CcSEcCtD
Cysteamine—Mental disorder—Doxorubicin—bone cancer	0.000218	0.00304	CcSEcCtD
Cysteamine—SST—Signaling Pathways—IGF1R—bone cancer	0.000217	0.00263	CbGpPWpGaD
Cysteamine—Convulsion—Methotrexate—bone cancer	0.000216	0.00303	CcSEcCtD
Cysteamine—Malnutrition—Doxorubicin—bone cancer	0.000216	0.00302	CcSEcCtD
Cysteamine—Erythema—Doxorubicin—bone cancer	0.000216	0.00302	CcSEcCtD
Cysteamine—Anaemia—Epirubicin—bone cancer	0.000216	0.00302	CcSEcCtD
Cysteamine—Agitation—Epirubicin—bone cancer	0.000215	0.003	CcSEcCtD
Cysteamine—Tension—Doxorubicin—bone cancer	0.000212	0.00297	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000211	0.00295	CcSEcCtD
Cysteamine—Discomfort—Methotrexate—bone cancer	0.00021	0.00294	CcSEcCtD
Cysteamine—Nervousness—Doxorubicin—bone cancer	0.00021	0.00294	CcSEcCtD
Cysteamine—Leukopenia—Epirubicin—bone cancer	0.000209	0.00293	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—IGF1R—bone cancer	0.000208	0.00252	CbGpPWpGaD
Cysteamine—Confusional state—Methotrexate—bone cancer	0.000206	0.00287	CcSEcCtD
Cysteamine—Anaphylactic shock—Methotrexate—bone cancer	0.000204	0.00285	CcSEcCtD
Cysteamine—Convulsion—Epirubicin—bone cancer	0.000203	0.00283	CcSEcCtD
Cysteamine—Hypertension—Epirubicin—bone cancer	0.000202	0.00282	CcSEcCtD
Cysteamine—Nervous system disorder—Methotrexate—bone cancer	0.0002	0.0028	CcSEcCtD
Cysteamine—Anaemia—Doxorubicin—bone cancer	0.0002	0.0028	CcSEcCtD
Cysteamine—Agitation—Doxorubicin—bone cancer	0.000199	0.00278	CcSEcCtD
Cysteamine—Skin disorder—Methotrexate—bone cancer	0.000198	0.00277	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000198	0.00276	CcSEcCtD
Cysteamine—Discomfort—Epirubicin—bone cancer	0.000197	0.00275	CcSEcCtD
Cysteamine—Anorexia—Methotrexate—bone cancer	0.000194	0.00272	CcSEcCtD
Cysteamine—Leukopenia—Doxorubicin—bone cancer	0.000194	0.00271	CcSEcCtD
Cysteamine—Confusional state—Epirubicin—bone cancer	0.000192	0.00269	CcSEcCtD
Cysteamine—Anaphylactic shock—Epirubicin—bone cancer	0.000191	0.00267	CcSEcCtD
Cysteamine—Convulsion—Doxorubicin—bone cancer	0.000187	0.00262	CcSEcCtD
Cysteamine—Nervous system disorder—Epirubicin—bone cancer	0.000187	0.00262	CcSEcCtD
Cysteamine—Hypertension—Doxorubicin—bone cancer	0.000187	0.00261	CcSEcCtD
Cysteamine—Skin disorder—Epirubicin—bone cancer	0.000185	0.00259	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000183	0.00256	CcSEcCtD
Cysteamine—Discomfort—Doxorubicin—bone cancer	0.000182	0.00254	CcSEcCtD
Cysteamine—Anorexia—Epirubicin—bone cancer	0.000182	0.00254	CcSEcCtD
Cysteamine—Somnolence—Methotrexate—bone cancer	0.000181	0.00253	CcSEcCtD
Cysteamine—Dyspepsia—Methotrexate—bone cancer	0.000179	0.00251	CcSEcCtD
Cysteamine—Confusional state—Doxorubicin—bone cancer	0.000178	0.00249	CcSEcCtD
Cysteamine—Decreased appetite—Methotrexate—bone cancer	0.000177	0.00248	CcSEcCtD
Cysteamine—Anaphylactic shock—Doxorubicin—bone cancer	0.000176	0.00247	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Methotrexate—bone cancer	0.000176	0.00246	CcSEcCtD
Cysteamine—Fatigue—Methotrexate—bone cancer	0.000176	0.00246	CcSEcCtD
Cysteamine—Nervous system disorder—Doxorubicin—bone cancer	0.000173	0.00242	CcSEcCtD
Cysteamine—Skin disorder—Doxorubicin—bone cancer	0.000171	0.0024	CcSEcCtD
Cysteamine—Somnolence—Epirubicin—bone cancer	0.00017	0.00237	CcSEcCtD
Cysteamine—Anorexia—Doxorubicin—bone cancer	0.000168	0.00235	CcSEcCtD
Cysteamine—Feeling abnormal—Methotrexate—bone cancer	0.000168	0.00235	CcSEcCtD
Cysteamine—Dyspepsia—Epirubicin—bone cancer	0.000168	0.00235	CcSEcCtD
Cysteamine—Gastrointestinal pain—Methotrexate—bone cancer	0.000167	0.00233	CcSEcCtD
Cysteamine—Decreased appetite—Epirubicin—bone cancer	0.000166	0.00232	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Epirubicin—bone cancer	0.000165	0.0023	CcSEcCtD
Cysteamine—Fatigue—Epirubicin—bone cancer	0.000164	0.0023	CcSEcCtD
Cysteamine—Constipation—Epirubicin—bone cancer	0.000163	0.00228	CcSEcCtD
Cysteamine—Urticaria—Methotrexate—bone cancer	0.000162	0.00226	CcSEcCtD
Cysteamine—Abdominal pain—Methotrexate—bone cancer	0.000161	0.00225	CcSEcCtD
Cysteamine—Body temperature increased—Methotrexate—bone cancer	0.000161	0.00225	CcSEcCtD
Cysteamine—Feeling abnormal—Epirubicin—bone cancer	0.000157	0.0022	CcSEcCtD
Cysteamine—SST—Signaling Pathways—KIT—bone cancer	0.000157	0.00191	CbGpPWpGaD
Cysteamine—Somnolence—Doxorubicin—bone cancer	0.000157	0.00219	CcSEcCtD
Cysteamine—Gastrointestinal pain—Epirubicin—bone cancer	0.000156	0.00218	CcSEcCtD
Cysteamine—Dyspepsia—Doxorubicin—bone cancer	0.000155	0.00217	CcSEcCtD
Cysteamine—Decreased appetite—Doxorubicin—bone cancer	0.000153	0.00215	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000152	0.00213	CcSEcCtD
Cysteamine—Fatigue—Doxorubicin—bone cancer	0.000152	0.00213	CcSEcCtD
Cysteamine—Urticaria—Epirubicin—bone cancer	0.000152	0.00212	CcSEcCtD
Cysteamine—Constipation—Doxorubicin—bone cancer	0.000151	0.00211	CcSEcCtD
Cysteamine—Body temperature increased—Epirubicin—bone cancer	0.000151	0.00211	CcSEcCtD
Cysteamine—Abdominal pain—Epirubicin—bone cancer	0.000151	0.00211	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—KIT—bone cancer	0.000151	0.00183	CbGpPWpGaD
Cysteamine—Hypersensitivity—Methotrexate—bone cancer	0.00015	0.0021	CcSEcCtD
Cysteamine—SST—Signaling Pathways—BRAF—bone cancer	0.000148	0.0018	CbGpPWpGaD
Cysteamine—Asthenia—Methotrexate—bone cancer	0.000146	0.00204	CcSEcCtD
Cysteamine—Feeling abnormal—Doxorubicin—bone cancer	0.000145	0.00203	CcSEcCtD
Cysteamine—Gastrointestinal pain—Doxorubicin—bone cancer	0.000144	0.00202	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—EGFR—bone cancer	0.000143	0.00174	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—BRAF—bone cancer	0.000142	0.00172	CbGpPWpGaD
Cysteamine—Hypersensitivity—Epirubicin—bone cancer	0.000141	0.00197	CcSEcCtD
Cysteamine—Urticaria—Doxorubicin—bone cancer	0.00014	0.00196	CcSEcCtD
Cysteamine—Abdominal pain—Doxorubicin—bone cancer	0.00014	0.00195	CcSEcCtD
Cysteamine—Body temperature increased—Doxorubicin—bone cancer	0.00014	0.00195	CcSEcCtD
Cysteamine—Diarrhoea—Methotrexate—bone cancer	0.000139	0.00195	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—EGFR—bone cancer	0.000137	0.00167	CbGpPWpGaD
Cysteamine—Asthenia—Epirubicin—bone cancer	0.000137	0.00191	CcSEcCtD
Cysteamine—Dizziness—Methotrexate—bone cancer	0.000135	0.00188	CcSEcCtD
Cysteamine—Diarrhoea—Epirubicin—bone cancer	0.000131	0.00183	CcSEcCtD
Cysteamine—Hypersensitivity—Doxorubicin—bone cancer	0.00013	0.00182	CcSEcCtD
Cysteamine—Vomiting—Methotrexate—bone cancer	0.00013	0.00181	CcSEcCtD
Cysteamine—Rash—Methotrexate—bone cancer	0.000129	0.0018	CcSEcCtD
Cysteamine—Dermatitis—Methotrexate—bone cancer	0.000128	0.0018	CcSEcCtD
Cysteamine—Headache—Methotrexate—bone cancer	0.000128	0.00179	CcSEcCtD
Cysteamine—Asthenia—Doxorubicin—bone cancer	0.000127	0.00177	CcSEcCtD
Cysteamine—Dizziness—Epirubicin—bone cancer	0.000126	0.00176	CcSEcCtD
Cysteamine—SST—Signaling Pathways—MDM2—bone cancer	0.000124	0.0015	CbGpPWpGaD
Cysteamine—Vomiting—Epirubicin—bone cancer	0.000121	0.0017	CcSEcCtD
Cysteamine—Nausea—Methotrexate—bone cancer	0.000121	0.00169	CcSEcCtD
Cysteamine—Diarrhoea—Doxorubicin—bone cancer	0.000121	0.00169	CcSEcCtD
Cysteamine—Rash—Epirubicin—bone cancer	0.00012	0.00168	CcSEcCtD
Cysteamine—Dermatitis—Epirubicin—bone cancer	0.00012	0.00168	CcSEcCtD
Cysteamine—Headache—Epirubicin—bone cancer	0.000119	0.00167	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—MDM2—bone cancer	0.000119	0.00144	CbGpPWpGaD
Cysteamine—Dizziness—Doxorubicin—bone cancer	0.000117	0.00163	CcSEcCtD
Cysteamine—Nausea—Epirubicin—bone cancer	0.000113	0.00158	CcSEcCtD
Cysteamine—Vomiting—Doxorubicin—bone cancer	0.000112	0.00157	CcSEcCtD
Cysteamine—Rash—Doxorubicin—bone cancer	0.000111	0.00156	CcSEcCtD
Cysteamine—Dermatitis—Doxorubicin—bone cancer	0.000111	0.00155	CcSEcCtD
Cysteamine—Headache—Doxorubicin—bone cancer	0.000111	0.00155	CcSEcCtD
Cysteamine—SST—Signaling Pathways—JUN—bone cancer	0.000108	0.00131	CbGpPWpGaD
Cysteamine—Nausea—Doxorubicin—bone cancer	0.000105	0.00147	CcSEcCtD
Cysteamine—SST—Signaling Pathways—MMP9—bone cancer	0.000105	0.00127	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—JUN—bone cancer	0.000103	0.00125	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—MMP9—bone cancer	0.0001	0.00122	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—EGFR—bone cancer	8.45e-05	0.00103	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—EGFR—bone cancer	8.11e-05	0.000985	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—TP53—bone cancer	7.1e-05	0.000863	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—TP53—bone cancer	6.81e-05	0.000827	CbGpPWpGaD
